Skip to main content
OpenTrials
Completed

NCT Number: NCT01812902

Prospective Study Comparing Extended With Limited Pelvic Lymphadenectomy in Intermediate and High Risk Prostate Cancer Patients Undergoing Radical Prostatectomy

Prostate cancer is currently the second most common cause of cancer death in men in Western countries. Lymphadenectomy is the gold standard procedure for staging pelvic lymph node and is classically indicated in intermediate and high risk prostate cancer patients and is held at the same time of prostatectomy. A traditionally pelvic lymphadenectomy covers the obturator chain bilaterally. Recently, some studies have demonstrated the existence of lymph node involvement outside the traditional boundaries of classical lymphadenectomy, recommending therefore extended dissection; this also includes the external / internal / common iliac chains and presacral. Thus lymphadenectomy, according to these authors, would also has a therapeutic role, besides helping in better staging. Although some retrospective studies report an association between lymphadenectomy and tumor progression, the exact impact of extended lymphadenectomy in oncological outcome of patients with prostate cancer is not clearly established, mainly by lack of prospective randomized studies on the subject . The study objectives are to compare the oncologic results of extended lymphadenectomy versus limited in order to elucidate the role of extended dissection in lymph node staging and results of treatment in terms of increased tumor cure. The investigators also intend to identify patients who may benefit from oncologically extended procedure. To do this, the investigators will evaluate prospectively patients diagnosed with prostate cancer at intermediate or high risk indicating lymphadenectomy and radical prostatectomy. These patients will be randomized to the extended versus limited lymphadenectomy and the investigators will compare the lymph node metastasis and pattern of spread of prostate cancer, as well as biochemical relapse-free survival, freedom from progression to metastasis and cancer-specific survival.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Instituto do Cancer do Estado de São Paulo

São Paulo, 01246-000, Brazil

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Prostate Cancer patients with intermediate or high risk and with indication of radical prostatectomy and LND
  • Absence of bone metastasis or other organ imaging test (MRI or scintigraphy)
  • Absence of hormone treatment
  • Absence of radiotherapy
  • Signing an informed consent
  • Availability and adequacy of lymph node tissue samples to perform the immunohistochemical

Exclusion criteria

  • Life expectancy less than 10 years
  • Absence of clinical conditions for the procedure
  • Laparoscopic or perineal surgery
  • Presence of bone or visceral metastasis
  • Neoadjuvant treatment
  • Another malignant neoplasia
  • Prior abdominal or pelvic surgery

Treatment and study plan

radical prostatectomy

Procedure

Primary outcomes

  1. Biochemical relapse-free survival

    Time frame: Five years

Secondary outcomes

  1. Staging

    Time frame: One Month

    At the moment of the pathological analysis We will do immunohistochemistry to detect micro metastasis

  2. Cancer specific survival

    Time frame: 10 years

Other outcomes

  1. Spread pattern of prostate cancer

    Time frame: One Month

  2. Metastasis free survival

    Time frame: Ten years

Sponsors and collaborators

Lead sponsor

University of Sao Paulo

Other

Collaborators

  • Fundação de Amparo à Pesquisa do Estado de São Paulo

Registry information

Official study title

Prospective Randomized Study Comparing Extended With Limited Pelvic Lymphadenectomy in Intermediate and High Risk Prostate Cancer Patients Undergoing Radical Prostatectomy

Acronym: LFD

Important dates

Study start
2012
Primary completion
2018
Study completion
2018
First posted
Mar 18, 2013
Registry last updated
May 14, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.